Strensiq
Strensiq ingredients
| Active ingredient | Strength |
|---|---|
| Asfotase Alfa | 40 mg/mL, 18 mg/.45mL, 80 mg/.8mL, 28 mg/.7mL |
What Strensiq is used for
The FDA lists the approved uses on the official label (below). In the EU, asfotase alfa is approved as Strensiq for:
Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Strensiq
- Generic name
- Asfotase alfa
- Made by
- Alexion Pharmaceuticals, Inc.
- Forms
- Solution
- Given
- Subcutaneous
- Drug class
- Tissue-nonspecific Alkaline Phosphatase
- FDA approval
- Biologic licence (BLA) BLA125513
- On the US market since
- 2015
Official information
- Strensiq prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Asfotase alfa)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Strensiq?
Strensiq (Asfotase alfa) is a specialist medicine made by Alexion Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Strensiq?
Strensiq contains Asfotase Alfa (40 mg/mL, 18 mg/.45mL, 80 mg/.8mL, 28 mg/.7mL).
Is Strensiq approved in Europe?
The same active substance is approved in the EU as Strensiq.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA